About
AAV capsid Gene Therapy
Areas of Focus
Categories
Virus TechnologyGene Therapy, RNA & Peptide TherapyBoston & New England
Team (15)
Alfred Sandrock
President and Chief Executive Officer
Voyager Therapeutics
team_memberexecutive
Catherine J
Voyager Therapeutics
team_member
George Scangos
Voyager Therapeutics
team_member
Glenn Pierce
Voyager Therapeutics
team_member
Grace E
Voyager Therapeutics
team_member
James Geraghty
Voyager Therapeutics
team_member
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
2
As Collaborator
4
Total Enrollment
111
By Phase
PHASE1/PHASE2: 1PHASE1: 4
By Status
COMPLETED: 4RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06874621Lead Sponsor
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
PHASE1/PHASE2Recruiting
52 participants
Started: Mar 3, 2025 · Completed: May 31, 2027
NCT04885114Lead Sponsor
Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease
PHASE1Withdrawn
Started: Jul 30, 2021 · Completed: Dec 30, 2024
NCT03562494Collaborator
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
PHASE1Completed
14 participants
Started: Oct 17, 2018 · Completed: Oct 30, 2024
NCT03733496Collaborator
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
N/ACompleted
14 participants
Started: Aug 24, 2018 · Completed: Jul 18, 2023
NCT03065192Collaborator
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
PHASE1Completed
16 participants
Started: May 11, 2017 · Completed: Aug 10, 2021
Locations (1)
Headquarters
Lexington, MA, United States
Map
Loading map...